News for November 2013

News Archive

Researchers Solve a Mystery about Type 2 Diabetes Drug with Assistance from AB SCIEX Mass Spectrometry Technologies Researchers Solve a Mystery about Type 2 Diabetes Drug with Assistance from AB SCIEX Mass Spectrometry Technologies

Researchers from St. Vincent’s Institute of Medical Research in Melbourne, Australia, in collaboration with researchers at McMaster University in Canada, are reportedly the first to discover how the type 2 diabetes drug metformin actually works, providing a molecular understanding that could lead to the development of more effective therapies. Mass spectrometry technologies from AB SCIEX, a global leader in analytical technologies, played a critical role in the analysis that led to this breakthrough finding. The research is published in this month’s issue of the journal Nature Medicine.

Swedish technological breakthrough poised to open new field in protein science research Swedish technological breakthrough poised to open new field in protein science research

Yet another major contribution from the Stockholm-Uppsala region to accelerating personalized medicine

Anti-coagulants work better with genetic testing, study finds Anti-coagulants work better with genetic testing, study finds

The effectiveness of one of the most widely used anti-coagulant drugs can be improved if genotype testing is carried out before the dose is decided, according to the findings of a new study from the University of Liverpool, and its collaborators, the Universities of Newcastle and Uppsala.

Probe’s signs MicroEye® -based continuous glucose monitoring systems development deal with Czech BVT Technologies Probe’s signs MicroEye® -based continuous glucose monitoring systems development deal with Czech BVT Technologies

Probe Scientific Ltd, an emerging UK medical device developer, today announced that it had signed a development agreement with BVT Technologies of Brno

Lab Innovations 2013 a Runaway Success Lab Innovations 2013 a Runaway Success

Lab Innovations - the UK’s only show dedicated to the latest laboratory technology & consumables, analytical & biotech equipment – which took place last week at the NEC, Birmingham, was a huge success.

Antibiotics – do you think they’re a cure for the common cold? Antibiotics – do you think they’re a cure for the common cold?

An Ipsos MORI poll commissioned by the Royal Society of Chemistry has shown that 74% of the public believe that a major research and development effort is needed to create new antibiotics for fighting infectious disease.

Prize highlights alternatives to animal testing for toxicology Prize highlights alternatives to animal testing for toxicology

Two technologies which assess the impact of chemicals and pollutants on the lungs and skin without the need for animal testing are joint winners of the 2013 Lush Science Prize.

immatics and Roche sign cancer vaccine and immunotherapy collaboration immatics and Roche sign cancer vaccine and immunotherapy collaboration

Collaboration spans the discovery, development and commercialisation of cancer vaccines and other cancer immunotherapies in gastric, lung and prostate cancer

Nicox launches Sjö™ in the US and partners with the Sjögren’s Syndrome Foundation Nicox launches Sjö™ in the US and partners with the Sjögren’s Syndrome Foundation

Nicox launches Sjö™, an advanced diagnostic for early detection of Sjögren’s Syndrome, a serious, progressive and underdiagnosed autoimmune disease US eye care professionals are uniquely positioned to identify Sjögren’s Syndrome as dry eye is a common early symptom

Petra Wilson appointed Chief Executive of the International Diabetes Federation Petra Wilson appointed Chief Executive of the International Diabetes Federation

The International Diabetes Federation (IDF) has appointed Dr. Petra Wilson as its Chief Executive Officer. Petra joins IDF from Cisco, where she was Senior Director of the European Health and Care Business Solutions team.

The British Government and pharmaceutical companies have agreed a new five-year, multi-billion pricing deal that will introduce a fixed limit on NHS spend on branded medicines The British Government and pharmaceutical companies have agreed a new five-year, multi-billion pricing deal that will introduce a fixed limit on NHS spend on branded medicines

The British Government and pharmaceutical companies have agreed a new five-year, multi-billion pricing deal that will introduce a fixed limit on NHS spend on branded medicines for the first time ever with all additional expenditure above this level paid for by industry.

REDX Agrees Pioneering MRSA Deal With NHS REDX Agrees Pioneering MRSA Deal With NHS

Drug development company Redx Pharma has today reached a landmark agreement with the Royal Liverpool and Broadgreen University Hospitals Trust to work together on new drugs to combat the growing threat of anti-biotic resistance.

Drug Discovery Today: November Issue Drug Discovery Today: November Issue

The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.

CRT Pioneer Fund Collaborates With Chroma Therapeutics To Develop Cancer Drugs Targeting The Immune System CRT Pioneer Fund Collaborates With Chroma Therapeutics To Develop Cancer Drugs Targeting The Immune System

The Cancer Research Technology Pioneer Fund (CPF) has announced a collaboration with Chroma Therapeutics Ltd to develop cancer drugs targeting macrophages – white blood cells – associated with tumours.This investment by the CPF will accelerate the development of a promising ‘lead’ molecule – taking it from the laboratory into clinical trials for patients.